submit news    HOME | FEEDBACK  


« NAVIGATION »
NEWS

- Bio/Medicine

- Chemicals

- Defense

- Drug Delivery

- Education

- Electronics

- Energy

- Events

- Grants

- Industry

- Investment

- Litigation

- Materials

- MEMS

- Nanofabrication

- Nanoparticles

- Nanotubes

- Optics

- Partnership

- Patent

- Products

- Quantum dots

- Research

- Smart Dust

- Software
COMPANIES
EVENTS

- Browse by Month

- Current Shows

- Previous Shows

- Submit Events
FEEDBACK
ADVERTISE
LINK TO US

« PARTNERS »
Become A Nanotechwire Partner

FEI Company

Veeco Instruments

Nano Science and Technology Institute

National Nanotechnology Initiative

Nanotechnology at Zyvex

Want to see your Company or Organization listed above? Become A Nanotechwire Partner Today - click here
« NEWSLETTER »



« SEARCH »







11/12/2006 10:33:34 AM
Perfecting Targeted Nanoparticles for Anticancer Therapy

Though researchers have made substantial progress in developing drug-ferrying nanoparticles that successfully target tumor cells in living animals, including humans, investigators have only now started the detailed work needed to identify formulation parameters that would optimize drug delivery to malignant cells. Now, in one of the first studies of its kind, a team of scientists at the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE) have performed systematic experiments aimed at identifying how nanoparticle formulations affect drug delivery in the body.

Reporting its work in the journal Biomaterials, a team of researchers led by Omid Farokhzad, M.D., of the Harvard Medical School and a member of the MIT-Harvard CCNE, and Robert Langer, Ph.D., of the Massachusetts Institute of Technology and co-principal investigator of the MIT-Harvard CCNE, studied the effects of altering nanoparticle polymer composition, drug loading, and solvents on the ability of the resulting nanoparticles to target and deliver drugs to tumors. As a targeting agent for all the polymer nanoparticles studied, the researchers used a molecule that recognizes the prostate-specific membrane antigen.

The main goal of this study was to develop formulation parameters that would control the size of the resulting polymer nanoparticles, which the investigators believe play a major role in optimizing tumor targeting. The researchers prepared their nanoparticles from a poly(d,l-lactide-co-glycolide)-block-poly(ethylene glycol), a biocompatible material that the team had developed earlier. Experimenting with a variety of polymer concentrations and solvent mixtures, the researchers found for the first time that they could systematically control the size of the resulting polymers. The results were so consistent that the investigators believe that they may have developed a broadly applicable approach to reproducibly tuning the size of polymer nanoparticles during their formulation.

In a final experiment, the researchers added the targeting agent to their optimized nanoparticles. The targeted nanoparticles were able to significantly increase drug delivery to human prostate tumors growing in mice.

This work, which was supported by the National Cancer Institute, is detailed in a paper titled, “Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery.” Investigators from the Massachusetts Institute of Technology and the Harvard Medical School also participated in this study. This paper was published online in advance of print publication. An abstract is available through PubMed.

View abstract.

Other Headlines from Harvard University ...
 - Engineers create vibrant colors in vertical silicon nanowires
 - Hand-held NMR Instrument Yields Rapid Analysis of Human Tumors
 - Oxford Nanopore announces licence agreement with Harvard University for graphene DNA sequencing
 - What ultra-tiny nanocircuits can do
 - Clay-armored bubbles may have formed first protocells

Other Headlines from Massachusetts Institute of Technology ...
 - Toward faster transistors
 - New sensor developed by MIT chemical engineers can detect tiny traces of explosives
 - Catching cancer with carbon nanotubes
 - Seeing below the surface
 - Koch Institute for Integrative Cancer Research dedicated at MIT

Other Headlines from NCI Alliance for Nanotechnology in Cancer ...
 - Tekmira and the National Cancer Institute Publish Promising Data Demonstrating the Anti-Tumor Activity of a Novel Cancer Target
 - NCI Awards $1.7 Million to Cancer Specialist at Children’s Hospital Los Angeles
 - Nanoparticles Enhance Detection of Circulating Tumor Cells
 - Hand-held NMR Instrument Yields Rapid Analysis of Human Tumors
 - Biodegradable Biopolymer Nanoparticles Hold Promise for Twin Attack on Breast Cancer

More Nanoparticles Headlines ...
 - UI study: Carbon black nanoparticles activate immune cells, causing cell death
 - Nanoparticles help scientists harvest light with solar fuels
 - Non-toxic nanoparticles may someday be used to fight cancer
 - 'DNAsomes' can deliver multiple drugs or genetic therapy
 - Building From the Ground Up, Researchers Construct RNA Nanoparticles to Safely Deliver Long-Lasting Therapy to Cells


« Back To List »

« GET LISTED »
- submit company
- submit news
- submit events
- advertise here

« EVENTS »
- More Events


Copyright © 2014 Nanotechwire.com | Privacy Policy |